<DOC>
	<DOCNO>NCT02633189</DOCNO>
	<brief_summary>The purpose study test whether combination bevacizumab erlotinib prolong progression free survival compare erlotinib alone first-line treatment patient non small cell lung cancer ( NSCLC ) activate mutation EGFR .</brief_summary>
	<brief_title>Study Comparing Bevacizumab + Erlotinib v Erlotinib Alone First Line Treatment Patients With EGFR Mutated Advanced Non Squamous Non Small Cell Lung Cancer</brief_title>
	<detailed_description>The co-primary objective assess investigator-assess , blinded independent centrally-reviewed progression-free survival .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>1 . Age ≥18 year 2 . Histological documentation primary non squamous lung carcinoma 3 . Stage IV IIIB disease supraclavicular metastatic node ( accord TNM 7th edition ) 4 . Activating epidermal growth factor receptor mutation ( exon19 deletion exon 21 L858R mutation activating/sensitizing mutation , exon 21 L861Q , exon 18 G719S , G719A G719C , exon 20 S768I V769L ) . EGFR mutation test must perform participate centre certify lab ( AIOMSIAPEC program European Quality Assurance [ EQA ] scheme ) 5 . Clinical radiologic evidence disease ( least one target non target lesion accord RECIST 1.1 ) 6 . ECOG performance status 0 2 7 . Life expectancy &gt; 3 month 8 . Use acceptable mean contraception men woman childbearing potential 9 . Written informed consent . 1 . EGFR T790M mutation alone exon 20 insertion unique mutation 2 . Tumors squamous component 3 . Prior chemotherapy medical treatment advance NSCLC ( previous neoadjuvant adjuvant chemotherapy allow &gt; 6 month randomisation ) 4 . Radiotherapy site reason within 28 day prior randomization ( palliative radiotherapy bone lesion allow ≥ 14 day randomization ) 5 . Fulldose anticoagulation warfarin 6 . Current recent ( within 10 day enrolment ) use aspirin ( &gt; 325 mg/day ) chronic use fulldose nonsteroidal antiinflammatory drug ( NSAIDs ) antiplatelet activity 7 . Receiving medication substance strong moderate inhibitor cytochrome P450 3A4 ( CYP3A4 ) prohibit = &lt; 7 day prior registration 8 . Receiving medication substance inducer CYP3A4 use inducer prohibit = &lt; 7 day prior registration 9 . Inadequate coagulation parameter : activate partial thromboplastin time ( APTT ) &gt; 1.5 x upper limit normal ( ULN ) INR &gt; 1.5 10 . Inadequate liver function , define : serum ( total ) bilirubin &gt; 1.5 x ULN AST/SGOT ALT/SGPT &gt; 2.5 x ULN 11 . Inadequate renal function , define : serum creatinine &gt; 2.0 mg/dl &gt; 177 micromol/l urine dipstick proteinuria &gt; 2+ . Patients &gt; = 1+ proteinuria baseline dipstick analysis must undergo 24hour urine collection must demonstrate ≤1g protein 24hour urine collection . 12 . Pregnancy breastfeed 13 . Inadequately control hypertension ( define systolic blood pressure &gt; 150 and/or diastolic blood pressure &gt; 100 mmHg antihypertensive medication ) 14 . History gross hemoptysis within 3 month prior randomization unless definitively treat surgery radiation 15 . History follow within 6 month prior randomisation : serious systemic disease , unstable angina , New York Heart Association ( NYHA ) Grade 2 great Congestive Heart Failure ( CHF ) , unstable symptomatic arrhythmia require medication , clinically significant peripheral vascular disease , abdominal fistula , gastrointestinal perforation , intraabdominal abscess 16 . Serious , nonhealing wound , ulcer , bone fracture 17 . Evidence bleed diathesis coagulopathy serious acute internal bleeding within 6 month prior randomization 18 . Central Nervous System ( CNS ) bleeding ; history clinical evidence CNS stroke ( hemorrhagic thrombotic ) within last 6 month 19 . Inpatient surgical procedure , open biopsy , significant traumatic injury within 28 day prior randomization 20 . Minor surgical procedure , fine needle aspiration core biopsy within 7 day prior randomization 21 . Anticipation need major surgical procedure course study 22 . Inability take oral medication requirement intravenous ( IV ) alimentation total parenteral nutrition lipid , prior surgical procedure affect absorption 23 . Evidence confusion disorientation , history major psychiatric illness may impair patient 's understanding Informed Consent Form his/her ability comply study requirement 24 . Any invasive malignancy within 5 year ( except adequately treat carcinoma situ cervix basal squamous cell skin cancer surgically resect prostate cancer normal PSA ) 25 . Brain metastasis 26 . Patients radiotherapy ≥ 4 week prior first dose study treatment , still experience acute toxic effect radiotherapy 27 . Known HIV positive patient ( patient acute chronic infection exclude ) 28 . Active HBV HCV infection ( patient chronic nonactive infection eligible ) 29 . Any already know inflammatory change surface eye baseline 30 . Any concomitant pathology laboratory alteration prevent contraindicate use erlotinib bevacizumab .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>stage IV</keyword>
	<keyword>stage IIIB</keyword>
	<keyword>EGFR mutation</keyword>
	<keyword>non-squamous</keyword>
	<keyword>liquid biopsy</keyword>
	<keyword>erlotinib</keyword>
	<keyword>bevacizumab</keyword>
</DOC>